Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)
Key facts
- Who runs it
- Cedars-Sinai Medical Center
- Where
- Indianapolis, Los Angeles, New Orleans, and Sacramento, United StatesSee the 4 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 20 Apr 2022
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
- Placebo Nasal Spray
- Record updated
- 11 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age greater than or equal to 18 years old, <80 years old
- Chronic Eustachian tube dysfunction defined as:; Symptoms in one or both ears > 3 months AND; ETDQ-7 score >14.5 AND; Type B, C, or As tympanometry
- Female subjects of childbearing potential must have a negative urine pregnancy test at screening and throughout the study duration
Who cannot take part
- Use of any additional intranasal medication
- Any history of temporomandibular disorder or prior surgery to the temporomandibular joint
- Known history of otologic surgery (excluding myringotomy or myringotomy tubes)
- Tympanic membrane perforation
- Any history of head and neck cancer
- Any history of head and neck irradiation
- Any medical condition that the investigator deems inappropriate for enrollment
- Age <18 years old
- Adhesive otitis media
- Cholesteatoma or significant retraction pocket
- Middle ear effusion
- Nasopharyngeal tumor
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial is currently available in United States.
- Indiana UniversityIndianapolis, United StatesContact: Elisa Illing, MDTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Missael VasquezTaking people
- Ochsner Health SystemNew Orleans, United StatesContact: Edward McCoul, MDTaking people
- Sacramento Ear, Nose & ThroatSacramento, United StatesContact: Rose KhalatyanTaking people
About the trial
What the trial wants to find out
Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).
The 2 groups in the trial
- Arm 1 (Placebo)Placebo, for comparison
Arm 1 (placebo) will get placebo spray per day.
Treatment: Placebo Nasal Spray
- Arm 2 (EDS-FLU)Existing treatment, for comparison
Arm 2 (EDS-FLU) will get 744 mcg of fluticasone propionate per day.
Treatment: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) in a Multi-center, Double-Blinded, Placebo-controlled Trial
- Criteria questions
- Built from NCT05275686, who can take part
- Record updated
- 11 March 2026